Silvercrest Asset Management’s Emergent Biosolutions EBS Stock Holding History

Silvercrest Asset Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-89,491	Closed	-$4.48M	–	844
2021 Q3	$4.48M	Sell	89,491 -2,462	-3%	-$149K	0.03%	396
2021 Q2	$5.79M	Sell	91,953 -197,007	-68%	-$12.7M	0.04%	371
2021 Q1	$26.8M	Buy	288,960 +6,276	+2%	+$643K	0.18%	155
2020 Q4	$25.3M	Buy	282,684 +29,373	+12%	+$2.7M	0.18%	147
2020 Q3	$26.2M	Sell	253,311 -25,342	-9%	-$2.73M	0.22%	127
2020 Q2	$22M	Sell	278,653 -53,173	-16%	-$3.96M	0.2%	137
2020 Q1	$19.2M	Sell	331,826 -67,156	-17%	-$3.87M	0.21%	133
2019 Q4	$21.5M	Buy	398,982 +73,404	+23%	+$3.98M	0.17%	150
2019 Q3	$17M	Buy	+325,578	New	+$15.2M	0.14%	168

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Silvercrest Asset Management's EBS Position: Q4 2021 in Review

Silvercrest Asset Management sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 89,491 shares — an estimated $4.48M sold.

Silvercrest Asset Management first reported a position in EBS in Q3 2019 and held it in 9 quarters. The position peaked at $26.8M in Q1 2021. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

Silvercrest Asset Management reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
Silvercrest Asset Management sold 89,491 Emergent Biosolutions shares in Q4 2021, an estimated $4.48M.
Silvercrest Asset Management first reported a position in Emergent Biosolutions in Q3 2019 and held it in 9 quarters.
Silvercrest Asset Management's Emergent Biosolutions position peaked at $26.8M in Q1 2021.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Silvercrest Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.